The estimated Net Worth of Sheila Gujrathi is at least $308 million dollars as of 27 September 2019. Sheila Gujrathi owns over 10,000 units of Turning Point Therapeutics Inc stock worth over $307,706,874 and over the last 9 years he sold TPTX stock worth over $0. In addition, he makes $56,250 as Chairman of the Board at Turning Point Therapeutics Inc.
Sign up
Sheila Gujrathi TPTX stock SEC Form 4 insiders trading
Sheila has made over 1 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of TPTX stock worth $168,000 on 27 September 2019.
The largest trade he's ever made was buying 10,000 units of Turning Point Therapeutics Inc stock on 27 September 2019 worth over $168,000. On average, Sheila trades about 1,000 units every 0 days since 2015. As of 27 September 2019 he still owns at least 4,048,242 units of Turning Point Therapeutics Inc stock.
You can see the complete history of Sheila Gujrathi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sheila Gujrathi biography
Dr. Sheila Gujrathi M.D. serves as Chairman of the Board of the Company. Dr. Gujrathi currently serves as the Co-Founder, President and Chief Executive Officer, and as a member of the Board of Directors, of Gossamer Bio, Inc., a public biopharmaceutical company. Previously, Dr. Gujrathi was the Chief Medical Officer of Receptos, Inc., a public biopharmaceutical company, a position she held from June 2011 until its acquisition by Celgene in August 2015. Dr. Gujrathi joined Receptos from Bristol-Myers Squibb Company, where she was Vice President of the Global Clinical Research Group in Immunology from 2008 until 2011. Prior to joining Bristol-Myers Squibb, Dr. Gujrathi worked at Genentech, Inc., where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group from 2002 until 2008. From 1999 until 2002, Dr. Gujrathi was a management consultant at McKinsey & Company in the healthcare practice, where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr. Gujrathi served on the Boards of Directors of Five Prime Therapeutics, Inc. from December 2015 to June 2019 and Ambrx from February 2014 to June 2015. Dr. Gujrathi received her B.S. with highest distinction in Biomedical Engineering and an M.D. from Northwestern University in its accelerated honors program in Medical Education. Dr. Gujrathi completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School. Dr. Gujrathi received additional training at the University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program.
What is the salary of Sheila Gujrathi?
As the Chairman of the Board of Turning Point Therapeutics Inc, the total compensation of Sheila Gujrathi at Turning Point Therapeutics Inc is $56,250. There are 11 executives at Turning Point Therapeutics Inc getting paid more, with Yi Larson having the highest compensation of $12,579,400.
How old is Sheila Gujrathi?
Sheila Gujrathi is 49, he's been the Chairman of the Board of Turning Point Therapeutics Inc since 2019. There are 13 older and 5 younger executives at Turning Point Therapeutics Inc. The oldest executive at Turning Point Therapeutics Inc is Garry Nicholson, 65, who is the Independent Director.
What's Sheila Gujrathi's mailing address?
Sheila's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.
Insiders trading at Turning Point Therapeutics Inc
Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado et Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.
What does Turning Point Therapeutics Inc do?
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
What does Turning Point Therapeutics Inc's logo look like?
Complete history of Sheila Gujrathi stock trades at Five Prime Therapeutics Inc, Turning Point Therapeutics Inc et Gossamer Bio
Turning Point Therapeutics Inc executives and stock owners
Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Yi Larson,
Chief Financial Officer, Executive Vice President -
Mohammad Hirmand,
Executive Vice President, Chief Medical Officer -
Annette North,
Executive Vice President, General Counsel, Secretary -
Dr. Athena Maria Countouriotis M.D.,
Pres, CEO & Director -
Andrew John Partridge,
Exec. VP & Chief Commercial Officer -
Carol Gallagher,
Independent Director -
Dr. Mohammad Hirmand,
Exec. VP & Chief Medical Officer -
Patrick Machado,
Independent Director -
Annette C. North Esq., LLB,
Exec. VP, Gen. Counsel & Company Sec. -
Dr. Siegfried Reich Ph.D.,
Exec. VP & Chief Scientific Officer -
Simeon George,
Independent Director -
Sheila Gujrathi,
Chairman of the Board -
Jacob Chacko,
Independent Director -
Jim Mazzola,
IR Contact Officer -
Garry Nicholson,
Independent Director -
Heather Adams,
Vice President of Human Resources -
Brian Baker,
Vice President - Finance and Administration -
Siegfried Reich,
Executive Vice President, Chief Scientific Officer -
Athena Countouriotis,
President, Chief Executive Officer, Director -
Dr. Jeffrey P. Whitten,
Sr. VP of Pre-Clinical Devel. -
Brian Sun J.D., M.S.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Dr. Gavin Hirst Ph.D.,
Sr. VP of Chemistry & Interim Chief Scientific Officer -
Raymond J. Furey J.D.,
Sr. VP & Chief Compliance Officer -
Dr. Adam D. Levy M.B.A., Ph.D.,
Sr. VP of Investor Relations & Corp. Communications -
Ed Gemo,
Sr. VP & Chief Information Officer -
Kyri K. Van Hoose,
VP of Accounting & Interim Principal Accounting Officer -
Paolo Tombesi,
Exec. VP & CFO -
Jingrong Jean Cui,
Director -
Plc Gsk,
Director -
Hongbo Lu,
Director -
Advisors Llc Orbi Med Capit...,
-
Asset Management, Lp Chen B...,
-
Carl L Gordon,
Director -
Barbara W. Bodem,
Director -
Mark J Alles,
Director -
Paolo Tombesi,
EVP & Chief Financial Officer -
Brian Sun,
SVP & General Counsel -
Steve M Sabus,
SVP & Chief Commercial Officer